Selective interstitial doxorubicin for recurrent glioblastoma

Poor delimitation from the viable brain, great genetic heterogeneity, lack of tumor vascularisation are factors that preclude intravenous chemotherapy. Interstitial chemotherapy could be a strategy to avoid a blood‐brain barrier and to assure a minimal dose concentration of the chemotherapy agent. Doxorubicin might be devoid of neurotoxic effects and still efficient on remaining far‐infiltrated tumor cells.